Your browser doesn't support javascript.
loading
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial.
Egle, Alexander; Melchardt, Thomas; Obrtlíková, Petra; Smolej, Lukás; Kozák, Tomás; Steurer, Michael; Andel, Johannes; Burgstaller, Sonja; Mikusková, Eva; Gercheva, Liana; Nösslinger, Thomas; Papajík, Tomás; Ladická, Miriam; Girschikofsky, Michael; Hrubisko, Mikulás; Jäger, Ulrich; Voskova, Daniela; Pecherstorfer, Martin; Králiková, Eva; Burcoveanu, Christina; Spasov, Emil; Petzer, Andreas; Mihaylov, Georgi; Raynov, Julian; Oexle, Horst; Zabernigg, August; Flochová, Emília; Palásthy, Stanislav; Stehlíková, Olga; Doubek, Michael; Altenhofer, Petra; Weiss, Lukas; Magnes, Teresa; Pleyer, Lisa; Klingler, Anton; Mayer, Jirí; Greil, Richard.
Afiliação
  • Egle A; Third Medical Department, Paracelsus Medical University Salzburg, Salzburg, Austria.
  • Melchardt T; Salzburg Cancer Research Institute (SCRI), Salzburg, Austria.
  • Obrtlíková P; Cancer Cluster Salzburg (CCS), Salzburg, Austria.
  • Smolej L; Third Medical Department, Paracelsus Medical University Salzburg, Salzburg, Austria.
  • Kozák T; Salzburg Cancer Research Institute (SCRI), Salzburg, Austria.
  • Steurer M; Cancer Cluster Salzburg (CCS), Salzburg, Austria.
  • Andel J; First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic.
  • Burgstaller S; Fourth Department of Internal Medicine - Hematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Králové, Czech Republic.
  • Mikusková E; Department of Internal Medicine - Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic.
  • Gercheva L; Department of Internal Medicine V, Medical University Innsbruck, Innsbruck, Austria.
  • Nösslinger T; Internal Medicine II, Hospital of Steyr, Steyr, Austria.
  • Papajík T; Department of Internal Medicine IV, Klinikum Wels-Grieskirchen GmbH, Wels, Austria.
  • Ladická M; Department of Hemato-oncology 2, National Cancer Institute Bratislava, Bratislava, Slovakia.
  • Girschikofsky M; Clinic of Hematology, University Hospital St Marina Varna, Varna, Bulgaria.
  • Hrubisko M; Third Medical Department for Hematology and Oncology, Hanusch Krankenhaus der Wiener Gebietskrankenkasse, Vienna, Austria.
  • Jäger U; Department of Hemato-oncology, University Hospital Olomouc, Olomouc, Czech Republic.
  • Voskova D; Department of Clinical Oncology 1, National Cancer Institute Bratislava, Bratislava, Slovakia.
  • Pecherstorfer M; Interne Abteilung, Ordensklinikum Linz GmbH, Elisabethinen, Linz, Austria.
  • Králiková E; Clinic of Hematology and Transfusiology, Slovak Medical University, University Hospital Bratislava, Bratislava, Slovakia.
  • Burcoveanu C; Department of Medicine I, Division of Hematology and Hemostaeology, Medical University Vienna, Vienna, Austria.
  • Spasov E; Department of Internal Medicine 3, Kepler Universitätsklinikum GmbH, Med Campus III., Linz, Austria.
  • Petzer A; Department of Internal Medicine 2, University Hospital Krems, Karl Landsteiner Private University of Health Sciences, Krems, Austria.
  • Mihaylov G; Department of Hematology, FNsP F D Roosevelta Banská Bystrica, Banska Bystrica, Slovakia.
  • Raynov J; Clinic of Haematology, Regional Institute of Oncology Iasi, Iasi, Romania.
  • Oexle H; Clinic of Hematology, UMHAT St George and Medical University Plovdiv, Plovdiv, Bulgaria.
  • Zabernigg A; Innere Medizin I, Ordensklinikum Linz GmbH, Linz, Austria.
  • Flochová E; Hematological Clinic NSHATHD Sofia, Queen Joanna University Hospital, Sofia, Bulgaria.
  • Palásthy S; Clinic of Medical Hematology, Military Medical Academy Sofia, Sofia, Bulgaria.
  • Stehlíková O; Innere Medizin, Landeskrankenhaus Hall, Hall in Tirol, Austria.
  • Doubek M; Innere Medizin II, Bezirkskrankenhaus Kufstein, Kufstein, Austria.
  • Altenhofer P; Department of Hematology and Transfusion, University Hospital Martin, Martin, Slovakia.
  • Weiss L; Department of Clinical Hematology, FNsP, J A Reimana Presov, Presov, Slovakia.
  • Magnes T; Faculty of Medicine and CEITEC, University Hospital Brno, Brno, Czech Republic.
  • Pleyer L; Faculty of Medicine and CEITEC, University Hospital Brno, Brno, Czech Republic.
  • Klingler A; Third Medical Department, Paracelsus Medical University Salzburg, Salzburg, Austria.
  • Mayer J; Salzburg Cancer Research Institute (SCRI), Salzburg, Austria.
  • Greil R; Cancer Cluster Salzburg (CCS), Salzburg, Austria.
Cancer Med ; 8(4): 1401-1405, 2019 04.
Article em En | MEDLINE | ID: mdl-30888118
ABSTRACT
No data are available regarding obesity and outcome in Chronic Lymphocytic Leukemia (CLL). We analyzed 263 patients from the AGMT CLL-8a Mabtenance trial for the impact of obesity. The trial included patients after rituximab-containing induction treatment in first or second line that had achieved at least a PR. A randomization to rituximab maintenance treatment (375 mg/m2 q3 months for 2 years) vs observation was performed. In this cohort 22% of the patients (58/263) were classified as obese. The baseline response to induction treatment was inferior in obese patients with a lower CR rate (43.1% vs 60.5% in obese vs non-obese, P = 0.018) and with a lower rate of patients achieving MRD negativity after chemoimmunotherapy induction treatment (19.6% vs 35.8%, P = 0.02). The PFS outcome of obese patients was significantly worse in the observation group of the trial (24 vs 39 months median PFS, P = 0.03). However, in the rituximab maintenance group the outcome for obese vs non-obese was not different (P = 0.4). In summary, obesity was overall associated with a worse outcome of chemoimmunotherapy induction. However, rituximab maintenance treatment seems to be able to overcome this negative effect.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Rituximab / Obesidade Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Med Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Áustria

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Rituximab / Obesidade Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Med Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Áustria